

29 July 2022

Radium-223 dichloride

Question 1

Please complete the table below:

Radium-223 dichloride service	
Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n)	Y
If yes, please list the indications for which it is used in your trust?	Metastatic castration resistant prostate cancer involving bone, following progression on Abiraterone/Enzalutamide +/- Docetaxel (if eligible)

Question 2

Please detail the number of patients that are treated with radium-223 dichloride in your trust:

Patient numbers	
Number of prostate cancer patients completing treatment with radium-223 dichloride per year	Number of 6th treatments per year: 2017: 21, 2018: 24, 2019: 11, 2020: 8, 2021: 19
Number of prostate cancer patients initiating radium-223 dichloride treatment per year	Number of 1st treatments per year: 2017: 40, 2018: 25, 2019: 19, 2020: 16, 2021: 31
What is the average number of cycles administered per patient in your service?	5
What is the waiting time before patients can receive radium-223 dichloride?	2 weeks
How many patients are initiated with cabazitaxel per year in your trust?	Approx 20

Question 3

In what department is molecular radiotherapy provided in your trust?

Administration	Radium-223 dichloride	¹⁷⁷ Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine	yes	n/a
Medical Physics	Yes – Nuclear Medicine is managed by Medical Physics	
Radiotherapy		
Oncology		
Urology		
Other		
N/A		

29 July 2022

Question 4

What codes are associated with molecular radiotherapy administration in your trust?

NHS codes	HRG	OPCS code
Radium-223 dichloride	NR223Y	

Question 5

Please complete the table below:

Who performs the administration of the treatment?	Radium-223 dichloride	177Lutetium based radioligand therapy for neuroendocrine tumours
CNS	No	
Technician	Yes	
NM nurse	Yes	
NM physicist	No	
NM Consultant	No	
Oncologist	Yes	
Other (please state)		

Question 6

Who holds the ARSAC licence in your trust?

Administration	(y/n)	Radium-223 dichloride	177Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine consultant	Y		
Clinical Oncologist	Y	Y	
Radiologist	Y	Y	Y
Other (please state speciality)			

Question 7

Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

Radiation safety (y/n)	Conducted in-house (If so, please provide the number of full-time equivalents providing these services in your centre)	Outsourced
Radioactive Waste Adviser (RWA)	Y – 3 certificated RWAs available	
Radiation Protection Adviser (RPA)	Y – 2 certificated RPAs available	
Medical Physics Expert (MPE)	Y – 5 MPEs available	

29 July 2022

Question 8

Please complete the table below:

Dosimetry	(y/n)	If yes, what is the schedule after each administration?	If yes, is this analysed in-house or outsourced?
Is dosimetry performed for radium-223 dichloride prostate cancer patients?	N		